For single intramuscular injection. The dose depends on the previously administered medetomidine or dexmedetomidine. Use of an appropriately graduated syringe is recommended to ensure accurate dosing when administering small volumes. Atipamezole is generally administered 15-60 minutes after medetomidine or dexmedetomidine injection.
Dogs: The dose of atipamezole hydrochloride (in µg per kg bodyweight) is five times that of the previous dose of medetomidine hydrochloride or ten times that of the dose of dexmedetomidine hydrochloride. Due to the fivefold concentration of the active ingredient (atipamezole hydrochloride) in this product compared to that of preparations containing 1 mg medetomidine hydrochloride per ml and the tenfold concentration compared to that of preparations containing 0.5 mg dexmedetomidine hydrochloride, an equal volume of each preparation is required.
Due to the 50-fold concentration compared to that of preparations containing 0.1 mg dexmedetomidine hydrochloride, a volume 5 times lower of the Alzane is required.
Dosage example dogs:
Medetomidine 1.0 mg/ml solution for injection dosage | Alzane 5.0 mg/ml solution for injection dosage |
0.04 ml/kg bodyweight (bw), corresponding with 40 μg/kg bw | 0.04 ml/kg bodyweight (bw), corresponding with 200 μg/kg bw |
Dexmedetomidine 0.5 mg/ml solution for injection dosage | Alzane 5.0 mg/ml solution for injection dosage |
0.04 ml/kg bodyweight (bw), corresponding with 20 μg/kg bw | 0.04 ml/kg bodyweight (bw), corresponding with 200 μg/kg bw |
Dexmedetomidine 0.1 mg/ml solution for injection dosage | Alzane 5.0 mg/ml solution for injection dosage |
0.2 ml/kg bodyweight (bw), corresponding with 20 μg/kg bw | 0.04 ml/kg bodyweight (bw), corresponding with 200 μg/kg bw |
Cats: The atipamezole hydrochloride dose (in µg per kg bodyweight) is 2.5 times that of the previous dose of medetomidine hydrochloride or five times that of the dose of dexmedetomidine hydrochloride. Due to the fivefold concentration of the active ingredient (atipamezole hydrochloride) in this product compared to that of preparations containing 1 mg medetomidine hydrochloride per ml and the tenfold concentration compared to that of preparations containing 0.5 mg dexmedetomidine hydrochloride, half the volume of the product to that of the previously administered medetomidine or dexmedetomidine should be given.
Due to the 50-fold concentration compared to that of preparations containing 0.1 mg dexmedetomidine hydrochloride, a volume 10 times lower of Alzane is required.
Dosage example cats:
Medetomidine 1.0 mg/ml solution for injection dosage | Alzane 5.0 mg/ml solution for injection dosage |
0.08 ml/kg bodyweight (bw), corresponding with 80 μg/kg bw | 0.04 ml/kg bodyweight (bw), corresponding with 200 μg/kg bw |
Dexmedetomidine 0.5 mg/ml solution for injection dosage | Alzane 5.0 mg/ml solution for injection dosage |
0.08 ml/kg bodyweight (bw), corresponding with 40 μg/kg bw | 0.04 ml/kg bodyweight (bw), corresponding with 200 μg/kg bw |
Dexmedetomidine 0.1 mg/ml solution for injection dosage | Alzane 5.0 mg/ml solution for injection dosage |
0.4 ml/kg bodyweight (bw), corresponding with 40 μg/kg bw | 0.04 ml/kg bodyweight (bw), corresponding with 200 μg/kg bw |
The recovery time for dogs and cats is shortened to approximately 5 minutes. The animals become mobile after approximately 10 minutes after administration of the product.